SL Science Reports First Half 2026 Financial Results
Biotechnology
Earnings
Merger:
Jun 15, 2026
Industry:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
SL Science Holding Limited Reports First Half 2026 Financial Results
Taipei, Taiwan - SL Science Holding Limited (NASDAQ: SLBT), a biomedical company specializing in innovative cellular and gene therapies, reported its financial results for the first half of 2026. The company experienced growth in net revenue and margin expansion following its recent business combination and Nasdaq listing.
... Read on — Members only
About SL Science Holding Ltd
SL Bio is a biomedical company focused on developing innovative cellular and gene therapies for cancer treatment and regenerative medicine. Leveraging proprietary technologies and strategic partnerships, the company is advancing next-generation immunotherapies and exosome-based products for both medical and consumer applications. SL Bio’s approach combines scientific expertise with a commitment to improving patient outcomes and addressing unmet needs in healthcare. SL Bio also offers ISO-certified, dermatologically tested cow milk-derived exosome-based products and plant extract products for skin and hair care, with commercial distribution in Asia.
More SLBT News
Biotechnology
Daily overview of upcoming SPAC and IPO events – from initial announcement to definitive agreement and public listing.
Discover last week’s SPAC and IPO highlights, key trends, and market updates. Stay informed with SpacStar.